Population
ANP-null mice and wild-type controls subjected to transverse aortic constriction; cardiac fibroblasts…
Comparison
Atrial natriuretic peptide, cGMP, and… vs Wild-type controls and untreated or TGF-beta1…
Design
Preclinical
Authors
Loading...
Extends ANP-PKG-Smad3 antifibrotic mechanism in animal models; human studies needed before clinical translation.
ANP exerts antifibrogenic effects in the heart by activating PKG, which phosphorylates Smad3 and prevents its TGF-beta1-induced nuclear translocation.
Li et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: